May 15, 2008 - EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, announced that Michael G. Kauffman, M.D., Ph.D., chief executive officer of EPIX, is scheduled to present an oral presentation entitled "Selective Serotonin-2B Receptor Antagonist PRX-08066 Improves Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease" at the International Conference of the American Thoracic Society in Toronto on Wednesday, May 21, 2008 at 2:50 p.m. ET. EPIX previously announced the results of a Phase 2a clinical trial of PRX-08066 in patients with pulmonary hypertension (PH) associated with chronic obstructive pulmonary disease (COPD)... EPIX Pharmaceuticals' Press Release -
